Pharmaceutical scientist with a PhD in Pharmaceutics. Founder and Director of M2M Pharmaceuticals Ltd since 2016. In past, worked for a CRO for 12 years in early-stage product development especially related to material science for inhaled drug delivery. Have worked in principles to cGMP as per the ICH Q8, Q9, Q10 and Q11.

Special Interests: 
Amorphous materials (intentional/unintentional)
Amorphous content determination with method development and validation
Inhalation drug delivery
Solid form selection
Batch-to-batch variability
Amorphous Solid Dispersion (ASD)
Co-crystallisation in solid-state
Early-stage product development